Literature DB >> 31704869

Impact of Acridine Orange in Patients With Soft Tissue Sarcoma Treated With Marginal Resection.

Hiroyuki Tsuchie1, Makoto Emori2, Naohisa Miyakoshi3, Hiroyuki Nagasawa3, Kyoji Okada4, Yasutaka Murahashi2, Emi Mizushima2, Junya Shimizu2, Toshihiko Yamashita2, Yoichi Shimada3.   

Abstract

BACKGROUND/AIM: Although few studies have shown the effectiveness of adjuvant therapy with acridine orange (AO) for soft tissue sarcoma (STS) patients, no study has investigated this among cases with marginal resection. The aim of the study was to evaluate the effectiveness of AO therapy directly by comparing it to marginal resection cases that did not receive AO. PATIENTS AND METHODS: This retrospective study included 19 and 33 patients with STS who received AO therapy (AO group) and marginal resection without AO therapy (non-AO group), respectively. The patients' clinical information was collected, and the clinical courses were compared.
RESULTS: The local recurrence rate in the AO group was significantly lower than that in the non-AO group (p<0.05). The local recurrence-free survival curves significantly differed between the two groups (p<0.05). High grade malignancy and no treatment with AO were identified as risk factors for local recurrence (p<0.05).
CONCLUSION: AO therapy strongly suppressed local recurrence after marginal resection of STS. Copyright
© 2019, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.

Entities:  

Keywords:  Acridine orange; marginal resection; soft tissue sarcoma

Mesh:

Substances:

Year:  2019        PMID: 31704869     DOI: 10.21873/anticanres.13849

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  3 in total

1.  Risk Factors of Early Distant Metastasis After Primary Tumor Treatment in Soft Tissue Sarcoma.

Authors:  Hiroyuki Tsuchie; Makoto Emori; Hiroyuki Nagasawa; Yasutaka Murahashi; Emi Mizushima; Junya Shimizu; Toshihiko Yamashita; Naohisa Miyakoshi
Journal:  In Vivo       Date:  2022 Sep-Oct       Impact factor: 2.406

2.  Impact of Acridine Orange in Patients With Local Recurrent Soft Tissue Sarcoma.

Authors:  Hiroyuki Tsuchie; Makoto Emori; Naohisa Miyakoshi; Kyoji Okada; Hiroyuki Nagasawa; Yasutaka Murahashi; Emi Mizushima; Junya Shimizu; Toshihiko Yamashita; Yoichi Shimada
Journal:  In Vivo       Date:  2020 Sep-Oct       Impact factor: 2.155

3.  Radiodynamic Therapy with Acridine Orange Is an Effective Treatment for Bone Metastases.

Authors:  Gemma Di Pompo; Katsuyuki Kusuzaki; Marco Ponzetti; Vito Ferdinando Leone; Nicola Baldini; Sofia Avnet
Journal:  Biomedicines       Date:  2022-08-05
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.